ubenimex has been researched along with Urinary Bladder Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, M; Guo, F; Liu, S; Liu, W; Liu, Y; Wang, X; Wu, R; Zhang, L; Zhang, Y | 1 |
| Blomgren, H; Edsmyr, F; Esposti, PL; Näslund, I | 1 |
| Akaza, H; Kobayashi, K; Niijima, T; Umeda, T; Yokoyama, H | 1 |
| Koshida, K; Kunimi, K; Uchibayashi, T; Yamamoto, H | 1 |
| Asakawa, M; Horii, A; Kyo, M; Maekawa, M; Yasumoto, R | 1 |
| Blomgren, H; Esposti, PL; Johansen, L; Lemming, O; Näslund, I | 1 |
| Aso, Y; Kitagawa, M; Suzuki, K; Tajima, A; Ushiyama, T | 1 |
| Aoyama, T; Furuya, S; Honma, A; Kato, S; Kumamoto, Y; Takatsuka, K; Tamiya, T; Tanda, H; Tsukamoto, T; Yokoyama, E | 1 |
| Aaskoven, O; Blomgren, H; Esposti, PL; Johansen, L; Näslund, I | 1 |
| Blomgren, H; Edsmyr, F; von Stedingk, LV; Wasserman, J | 1 |
| Hirokawa, I; Ichikawa, T; Ishihara, Y | 1 |
6 trial(s) available for ubenimex and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial.
Topics: Adjuvants, Immunologic; Aged; Blood Cell Count; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Leucine; Male; Middle Aged; Time Factors; Urinary Bladder Neoplasms | 1984 |
Adjuvant therapy with 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder--comparison between UFT therapy alone and UFT therapy in combination with Bestatin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Female; Humans; Isomerism; Leucine; Male; Middle Aged; Prospective Studies; Tegafur; Urinary Bladder Neoplasms | 1995 |
Adjuvant bestatin (Ubenimex) treatment following full-dose local irradiation for bladder carcinoma.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Leucine; Male; Middle Aged; Survival Analysis; Urinary Bladder Neoplasms | 1990 |
[Clinical research on prevention of recurrence of superficial bladder cancer--comparative study on clinical efficacy of bleomycin intravesical instillation and bestatin].
Topics: Adolescent; Adult; Aged; Animals; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Transitional Cell; Chemotherapy, Cancer, Regional Perfusion; Child; Child, Preschool; Dogs; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infant; Leucine; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Urinary Bladder Neoplasms | 1985 |
Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial.
Topics: Adjuvants, Immunologic; Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; Humans; Leucine; Male; Prospective Studies; Random Allocation; Urinary Bladder Neoplasms | 1987 |
Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients.
Topics: Adjuvants, Immunologic; Combined Modality Therapy; Humans; Immunoglobulins; In Vitro Techniques; Leucine; Leukocyte Count; Lymphocyte Activation; Lymphocytes; Prospective Studies; Random Allocation; Urinary Bladder Neoplasms | 1986 |
5 other study(ies) available for ubenimex and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Ubenimex, an APN inhibitor, could serve as an anti‑tumor drug in RT112 and 5637 cells by operating in an Akt‑associated manner.
Topics: Antineoplastic Agents; Apoptosis; CD13 Antigens; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Leucine; Proto-Oncogene Proteins c-akt; Signal Transduction; Urinary Bladder Neoplasms | 2018 |
Restoration of E-rosette formation by bestatin in patients with bladder cancer.
Topics: Adjuvants, Immunologic; Aged; Anti-Bacterial Agents; Humans; Immunity, Cellular; Leucine; Lymphocytes; Middle Aged; Rosette Formation; Urinary Bladder Neoplasms | 1980 |
Multidisciplinary treatment for bladder carcinoma--biological response modifiers and kampo medicines.
Topics: Adjuvants, Immunologic; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Combined Modality Therapy; Drugs, Chinese Herbal; Female; Humans; Immunologic Factors; Leucine; Male; Picibanil; Rats; Rats, Inbred Strains; Sizofiran; Urinary Bladder Neoplasms | 1991 |
[Hyperthermic treatment with peplomycin and bestatin in superficial bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Humans; Hyperthermia, Induced; Leucine; Male; Middle Aged; Peplomycin; Urinary Bladder Neoplasms | 1985 |
[Clinical studies of bestatin on genitourinary cancer].
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; Female; Humans; Kidney Neoplasms; Leucine; Male; Middle Aged; Penile Neoplasms; Prostatic Neoplasms; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms | 1985 |